keyword
MENU ▼
Read by QxMD icon Read
search

Aromatase and breast cancer

keyword
https://www.readbyqxmd.com/read/29223989/geographic-variation-of-adjuvant-breast-cancer-therapy-initiation-in-the-united-states-lessons-from-medicare-part-d
#1
John A Charlson, Emily L McGinley, Ann B Nattinger, Joan M Neuner, Liliana E Pezzin
Background: Drug utilization under Medicare Part D varies significantly by geographic region. This study examined the extent to which geographic variation in Part D plan characteristics contributes to the variation in choice of initial endocrine therapy agent among women with incident breast cancer. Methods: Two-stage multivariate regression analyses were applied to the 16,541 women identified from Medicare claims as having incident breast cancer in 2006-2007. The first stage determined the effect of state of residence on the probability of having an aromatase inhibitor (AI), as opposed to tamoxifen, as initial endocrine therapy...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29222346/adiposity-inflammation-and-breast-cancer-pathogenesis-in-asian-women
#2
Neil M Iyengar, I-Chun Chen, Xi K Zhou, Dilip D Giri, Domenick J Falcone, Lisle A Winston, Hanhan Wang, Samantha Williams, Yen-Shen Lu, Tsu-Hsin Hsueh, Ann-Lii Cheng, Clifford A Hudis, Ching-Hung Lin, Andrew J Dannenberg
Obesity is associated with white adipose tissue (WAT) inflammation in the breast, elevated levels of the estrogen biosynthetic enzyme, aromatase, and systemic changes that predispose to breast cancer development. We examined whether WAT inflammation and its associated systemic effects correlate with body fat levels in an Asian population where body mass index (BMI) is not an accurate assessment of obesity and cancer risk. We also investigated whether biologic differences could account for the greater proportion of premenopausal estrogen receptor (ER)-positive breast cancer in Asian versus western countries...
December 8, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/29214214/molecular-changes-in-premenopausal-oestrogen-receptor-positive-primary-breast-cancer-in-vietnamese-women-after-oophorectomy
#3
Ben P Haynes, Ophira Ginsburg, Qiong Gao, Elizabeth Folkerd, Maria Afentakis, Le Hong Quang, Pham Thi Han, Pham Hong Khoa, Nguyen Van Dinh, Ta Van To, Mark Clemons, Ian E Smith, Mitch Dowsett
For premenopausal women with primary ER + breast cancer, oophorectomy (OvX) is an evidence-based cost-effective option and is standard treatment in many countries. However, there is virtually no data describing the effects of OvX on breast tumour biology. We therefore, characterised the endocrine and genome-wide transcriptional impact of OvX in 56 premenopausal women with ER + breast cancer for 2 weeks prior to mastectomy. Plasma estradiol concentrations decreased from 406 ± 41 to 20.7 ± 2...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29212872/parotid-gland-an-unusual-site-of-breast-cancer-metastasis
#4
Thomas Rawet, Apurna Jegannathen, Soni Soumian
Parotid gland metastases from breast cancer are an extremely rare and unusual event with a limited number of cases recorded in the literature. A 71-year-old woman with a history of ductal adenocarcinoma of the left breast presented to the maxillofacial clinic with an asymptomatic swelling of the left parotid gland. The presentation occurred 21 years after she underwent treatment for recurrent breast cancer. Investigations led to the diagnosis of a breast cancer metastasis which was oestrogen receptor and progesterone receptor positive and negative...
December 5, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29212847/attempted-replication-of-snps-in-rankl-and-opg-with-musculoskeletal-adverse-events-during-aromatase-inhibitor-treatment-for-breast-cancer
#5
Jacqueline M Dempsey, Jingyue Xi, N Lynn Henry, James M Rae, Daniel L Hertz
Aromatase inhibitor (AI) therapy is highly efficacious in the treatment of estrogen receptor-positive breast cancer, however in a subset of patients AI use is discontinued due to drug-induced musculoskeletal adverse events (MS-AE). Several studies have investigated the role of germline single nucleotide polymorphisms on patients' risk of MS-AE's, however no associations have yet to be validated for translation into clinical practice. This study attempted to replicate SNPs in RANKL (rs7984870) and OPG (rs2073618) on the risk of AI-induced MS-AEs, and screen for secondary associations with MS-AE related treatment discontinuation and serum and urine markers of bone health...
December 6, 2017: Physiological Genomics
https://www.readbyqxmd.com/read/29205077/forty-years-of-landmark-trials-undertaken-by-the-danish-breast-cancer-cooperative-group-dbcg-nationwide-or-in-international-collaboration
#6
Bent Ejlertsen, Birgitte Vrou Offersen, Jens Overgaard, Peer Christiansen, Maj-Britt Jensen, Niels Kroman, Ann Søgaard Knoop, Henning Mouridsen
BACKGROUND: Over the past 40 years the Danish Breast Cancer Cooperative Group (DBCG) has made significant contributions to improve outcome and to make treatment of patients with early breast cancer more tolerable through nationwide and international trials evaluating loco-regional and systemic treatments. These trials have been instrumental to establish standards for the treatment of early breast cancer. METHODS: The DBCG 82 trials had a global impact by documenting that the significant gain in loco-regional recurrence from postmastectomy radiation added to systemic therapy was associated with a reduction in distant recurrence and mortality in high-risk pre- and postmenopausal patients...
December 5, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29202611/aurora-kinase-a-as-a-possible-marker-for-endocrine-resistance-in-early-estrogen-receptor-positive-breast-cancer
#7
Anne E Lykkesfeldt, Benedikte R Iversen, Maj-Britt Jensen, Bent Ejlertsen, Anita Giobbie-Hurder, Birgit E Reiter, Tove Kirkegaard, Birgitte B Rasmussen
BACKGROUND: Cell culture studies have disclosed that the mitotic Aurora kinase A is causally involved in both tamoxifen and aromatase inhibitor resistant cell growth and thus may be a potential new marker for endocrine resistance in the clinical setting. MATERIAL AND METHODS: Archival tumor tissue was available from 1323 Danish patients with estrogen receptor (ER) positive primary breast cancer, who participated in the Breast International Group (BIG) 1-98 trial, comparing treatment with tamoxifen and letrozole and both in a sequence...
December 4, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29202405/potent-aromatase-inhibitors-and-molecular-mechanism-of-inhibitory-action
#8
Hongjun Kang, Xingqing Xiao, Chao Huang, Yan Yuan, Dongyan Tang, Xiaochang Dai, Xianghui Zeng
Estrogen is a significant factor in the maintenance and progression of hormone-dependent breast cancer. As well known, aromatase mediates the production of estrogen. Thus, inhibition of aromatase with chemical molecules has been considered to be an effective treatment for estrogen receptor-positive (ER+) breast cancer. In this work, we designed and synthesized a series of novel non-steroidal molecules containing 2-phenylindole scaffold and moiety of either imidazole or 1,2,4-triazole to enhance their binding capacity with the aromatase...
November 22, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29190006/trends-in-progression-free-survival-pfs-and-time-to-progression-ttp-over-time-within-first-line-aromatase-inhibitors-trials-in-hormone-receptor-positive-advanced-breast-cancer
#9
T Reinert, M Debiasi, J Bines, C H Barrios
BACKGROUND: Over the last 20 years, aromatase inhibitors (AI) have been tested in clinical trials as first-line therapy for hormone receptor-positive (HR-positive) advanced breast cancer (ABC), firstly as experimental arms, when they proved to be effective, and recently as control arms. This analysis aims to evaluate trends in progression-free survival (PFS) and time to progression (TTP) over time. PATIENTS AND METHODS: A literature review was conducted using the MEDLINE database to identify randomized controlled phase II or III trials which reported PFS or TTP of at least one arm using first-line AI HR-positive ABC patients...
November 30, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29189985/evaluation-of-the-effect-of-the-new-methoxy-stilbenes-on-expression-of-receptors-and-enzymes-involved-in-estrogen-synthesis-in-cancer-breast-cells
#10
Barbara Licznerska, Hanna Szaefer, Marcin Wierzchowski, Renata Mikstacka, Katarzyna Papierska, Wanda Baer-Dubowska
Our previous study showed that the new synthetic methoxy-stilbenes, 3,4,2'-trimethoxy-trans-stilbene (3MS), 3,4,2',4'-tetramethoxy-trans-stilbene (4MS), and 3,4,2',4',6'-pentamethoxy-trans-stilbene (5MS), modulate the constitutive expression of enzymes and receptors involved in estrogen metabolism in breast immortalized epithelial MCF10 cells. In this study, we evaluated the effect of 3MS, 4MS, and 5MS in comparison to resveratrol activity in MCF7 estrogen-dependent and MDA-MB-231 estrogen-independent breast cancer cell lines...
November 30, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/29187460/adjuvant-breast-cancer-treatments-induce-changes-in-homoarginine-level-a-prospective-observational-study
#11
Hanna Aula, Tanja Skyttä, Suvi Tuohinen, Tiina Luukkaala, Mari Hämäläinen, Vesa Virtanen, Pekka Raatikainen, Eeva Moilanen, Pirkko-Liisa Kellokumpu-Lehtinen
AIM: To identify patients with breast cancer at risk for cardiotoxicity, we evaluated homoarginine (HA) behavior during adjuvant treatment. PATIENTS AND METHODS: Eighty-one patients received radiotherapy (RT) with or without endocrine treatment, and 19 received chemotherapy, RT and endocrine therapy. Serum HA, asymmetric dimethylarginine (ADMA) and high-sensitivity cardiac troponin T (hscTnT) were measured and echocardiography was performed before chemotherapy, and before and after RT...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29177573/triptorelin-a-review-of-its-use-as-an-adjuvant-anticancer-therapy-in-early-breast-cancer
#12
James E Frampton
A 1-month formulation of the gonadotrophin-releasing hormone agonist (GnRHa) triptorelin (Decapeptyl®) has been approved in the EU as an adjuvant treatment in combination with tamoxifen or an aromatase inhibitor (AI), of endocrine-responsive, early-stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. This indication reflects the results of the 5-year SOFT and TEXT studies, especially SOFT, in which ovarian function suppression (OFS; mainly achieved with triptorelin) added to tamoxifen provided a significant benefit in the overall study population of premenopausal patients only after adjusting for prognostic factors...
November 25, 2017: Drugs
https://www.readbyqxmd.com/read/29177067/joint-symptoms-associated-with-anastrozole-and-letrozole-in-patients-with-breast-cancer-a-retrospective-comparative-study
#13
Yoshihito Morimoto, Shuhei Sarumaru, Yuko Oshima, Chiho Tsuruta, Kazuhiro Watanabe
Background: Joint symptoms are a common side effect of aromatase inhibitors. However, it is not known if the risk of these symptoms varies between the members of this drug class. The aim of this study was to compare the frequency of joint symptoms associated with anastrozole and that associated with letrozole. Methods: We retrospectively reviewed patients with breast cancer who were treated with anastrozole or letrozole at Tsukiji Breast Clinic, Japan, between April 2008 and July 2014...
2017: Journal of Pharmaceutical Health Care and Sciences
https://www.readbyqxmd.com/read/29168668/the-occurrence-of-fractures-after-adjuvant-treatment-of-breast-cancer-a-dbcg-register-study
#14
Bent Kristensen, Bent Ejlertsen, Maj-Britt Jensen, Henning T Mouridsen
BACKGROUND: Adjuvant treatment in breast cancer patients especially with aromatase inhibitors (AIs) has adverse effects on bone metabolism resulting in an increased occurrence of fractures. In order to demonstrate this occurrence, long-term follow-up studies are necessary. From several national registries in Denmark, it is possible to link data from different sources and analyze this issue. METHODS: A study cohort of 68,842 breast cancer patients prospectively diagnosed and registered in the Danish Breast Cancer Cooperative Group's database during the period 1995-2012 formed the basis of the analysis...
November 23, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29168427/neoadjuvant-letrozole-for-postmenopausal-estrogen-receptor-positive-her2-negative-breast-cancer-patients-a-study-from-the-danish-breast-cancer-cooperative-group-dbcg
#15
Signe Korsgaard Skriver, Anne-Vibeke Laenkholm, Birgitte Bruun Rasmussen, Jürgen Handler, Bo Grundtmann, Tove Filtenborg Tvedskov, Peer Christiansen, Ann S Knoop, Maj-Britt Jensen, Bent Ejlertsen
INTRODUCTION: Neoadjuvant endocrine treatment (NET) is a low-toxicity approach to achieve operability in locally advanced breast cancer, and to facilitate breast conservation in early breast cancer, particular in patients with highly estrogen receptor (ER) positive and HER2-negative disease. Here, we report the results obtained by neoadjuvant letrozole in patients with early breast cancer in a phase-II design. MATERIAL AND METHODS: A total of 119 postmenopausal women with ER-positive, HER2-negative operable breast cancer were assigned to four months of neoadjuvant letrozole before definitive surgery...
November 23, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29168353/genomic-risk-prediction-of-aromatase-inhibitor-related-arthralgia-in-patients-with-breast-cancer-using-a-novel-machine-learning-algorithm
#16
Raquel E Reinbolt, Stephen Sonis, Cynthia D Timmers, Juan Luis Fernández-Martínez, Ana Cernea, Enrique J de Andrés-Galiana, Sepehr Hashemi, Karin Miller, Robert Pilarski, Maryam B Lustberg
Many breast cancer (BC) patients treated with aromatase inhibitors (AIs) develop aromatase inhibitor-related arthralgia (AIA). Candidate gene studies to identify AIA risk are limited in scope. We evaluated the potential of a novel analytic algorithm (NAA) to predict AIA using germline single nucleotide polymorphisms (SNP) data obtained before treatment initiation. Systematic chart review of 700 AI-treated patients with stage I-III BC identified asymptomatic patients (n = 39) and those with clinically significant AIA resulting in AI termination or therapy switch (n = 123)...
November 23, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29164917/efficacy-and-safety-of-palbociclib-in-heavily-pretreated-patients-with-hr-her2-%C3%A2-metastatic-breast-cancer
#17
Marija Ban, Branka Petrić Miše, Ana Majić, Ivanka Dražić, Eduard Vrdoljak
AIM: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in combination with hormonal therapy improve progression free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. METHODS: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. RESULTS: A total of 58.3% patients achieved stable disease. No objective response was observed...
November 22, 2017: Future Oncology
https://www.readbyqxmd.com/read/29164377/systemic-and-local-effects-of-vaginal-dehydroepiandrosterone-dhea-ncctg-n10c1-alliance
#18
Debra L Barton, Lynne T Shuster, Travis Dockter, Pamela J Atherton, Jacqueline Thielen, Stephen N Birrell, Richa Sood, Patricia Griffin, Shelby A Terstriep, Bassam Mattar, Jacqueline M Lafky, Charles L Loprinzi
BACKGROUND: Dehydroepiandrosterone (DHEA) is helpful for treating vaginal symptoms. This secondary analysis evaluated the impact of vaginal DHEA on hormone concentrations, bone turnover, and vaginal cytology in women with a cancer history. METHODS: Postmenopausal women, diagnosed with breast or gynecologic cancer, were eligible if they reported at least moderate vaginal symptoms. Participants could be on tamoxifen or aromatase inhibitors (AIs). Women were randomized to 3...
November 21, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29158011/extended-adjuvant-intermittent-letrozole-versus-continuous-letrozole-in-postmenopausal-women-with-breast-cancer-sole-a-multicentre-open-label-randomised-phase-3-trial
#19
Marco Colleoni, Weixiu Luo, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Guy Jerusalem, Patrick Neven, Erika Hitre, Marie-Pascale Graas, Edda Simoncini, Claus Kamby, Alastair Thompson, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Christian Marth, Bettina Müller, Seamus O'Reilly, Vincenzo Di Lauro, Andrea Gombos, Thomas Ruhstaller, Harold Burstein, Karin Ribi, Jürg Bernhard, Giuseppe Viale, Rudolf Maibach, Manuela Rabaglio-Poretti, Richard D Gelber, Alan S Coates, Angelo Di Leo, Meredith M Regan, Aron Goldhirsch
BACKGROUND: In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole. We therefore hypothesised that extended intermittent use of adjuvant letrozole would improve breast cancer outcome compared with continuous use of letrozole in postmenopausal women. METHODS: We did the multicentre, open-label, randomised, parallel, phase 3 SOLE trial in 240 centres (academic, primary, secondary, and tertiary care centres) in 22 countries...
November 17, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29157627/letrozole-may-be-a-valuable-maintenance-treatment-in-high-grade-serous-ovarian-cancer-patients
#20
V Heinzelmann-Schwarz, A Knipprath Mészaros, S Stadlmann, F Jacob, A Schoetzau, K Russell, M Friedlander, G Singer, M Vetter
OBJECTIVES: Endocrine therapy is used as maintenance in estrogen receptor (ER) positive breast cancers and has been proposed in low-grade serous ovarian cancers (LGSOC). Here we examine a rationale for its use as maintenance in high-grade serous ovarian cancers (HGSOC). METHODS: We accessed the TCGA PANCAN dataset to evaluate the expression of ESR1. ESR1 expression data on all cancers (n=8901) and HGSOC (n=527) were followed by investigation of ER expression via immunohistochemistry (IHC) (n=4071)...
November 17, 2017: Gynecologic Oncology
keyword
keyword
48353
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"